top of page
Growth partner for biopharma & healthcare companies
-min.png)
-min.png)
What does Heylth do? Heylth is a growth partner for biotech, pharmaceutical and HCOs that combines healthcare expertise with practical AI applications. We help pharmaceutical, biotechnology, and healthcare teams adapt to the AI era, build internal capabilities, and execute multi-step work across research, content, and operations.
Who does heylth work with? We primarily partner with biopharma and medtech executives, as well as doctors and hospitals.
What geographic markets do you serve? We provide international perspectives with local priorities, specifically offering tailored services for the United States, Canada, India, and selected global markets.
How does Heylth help us know if our team is ready to implement AI? We offer the Heylth Pharma AI Score, which helps teams assess their current AI readiness, identify high-value use cases, and establish practical priorities for adoption. We also provide the Pharma AI Academy for practical AI learning programs.
What specific AI tools do you offer for life sciences? Our proprietary product portfolio includes: AI-VARK: Adaptive learning experiences tailored to visual, auditory, read/write, and kinesthetic preferences. AI-BRAND: AI-enabled strategic support for new launches and brand rejuvenation. AI-CONTENT: Tools to adapt approved healthcare knowledge into richer, personalized, and channel-ready engagement experiences. AI-STRAT: Structured, AI-enabled thinking for pharmaceutical strategy and planning.
How can Heylth help us prepare for investment or partnering events? We offer the JPM 2027 Partnering Accelerator to help life-science companies stand out during JPM Week. This program includes partner scoping, pre-meet outreach, crafting investor-ready materials, ensuring AI scanner compatibility, and providing executive preparation.
Can you support Medical and Pharmaceutical KOL (Key Opinion Leader) engagement? Yes, we have established programs for turning expert conversations into enduring scientific assets, such as combining KOL mapping, expert roundtables, and evidence research to develop published scientific reference books.
bottom of page